Author: admin
-
Yemen separatist leader accused of treason as Saudis strike forces
In December, the STC’s forces launched offensives to seize the eastern provinces of Hadramawt and al-Mahra from the government, saying they were necessary to “restore stability” in the south and combat the Houthis, al-Qaeda and Islamic State…
Continue Reading
-
Yemen separatist leader accused of treason as Saudis strike forces
The Saudi-backed presidential council in Yemen has expelled the leader of a separatist group and charged him with treason after he failed to fly to Riyadh for talks.
Six other members of the presidency accused Aidarous al-Zubaidi, head of the…
Continue Reading
-
McMaster discovery could lead to new treatments for drug-resistant fungal infections
McMaster discovery could lead to new treatments for drug-resistant fungal infections – Faculty of Health Sciences
Continue Reading
-
Samsung Makes Enterprise Debut at CES 2026 with Spatial Signage – Samsung Newsroom U.K.
Samsung Electronics, a global leader in technology, today announced that Spatial Signage has been recognized by the Consumer Technology Association (CTA)® as part of the CES Innovation Awards…
Continue Reading
-
Researchers Raise Concerns about Faster Aging, Possible Early-Onset Dementia, for Children and Young Adult Cancer Survivors
Adolescent and young adult cancer survivors age faster than their peers who did not have cancer, according to a new study, which also describes how accelerated aging occurs both at the cellular level and in brain function, such as memory,…
Continue Reading
-
Is ‘Open Stone Surgery with Intraoperative Nephroscopy’ a better alter
Introduction
The global incidence and prevalence of urolithiasis are steadily rising, creating a need for safe, effective, and affordable treatment options.1 This worldwide trend is now nearly the same in both developing and developed countries.
Continue Reading
-
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. ,Jan. 07, 2026 (GLOBE NEWSWIRE) —Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will present at the 44th AnnualJ.P. Morgan Healthcare Conference inSan Francisco onWednesday, January 14, 2026 at9:00 a.m. PT .A live webcast will be available on the Events and Presentations page in the Investors & Media section of Intellia’s website, www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for approximately 30 days.
About
Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.Intellia Contacts:
Investors:
Jason Fredette Vice President, Investor Relations and Corporate CommunicationsIntellia Therapeutics, Inc.
jason.fredette@intelliatx.comMedia:
Matt Crenson TenBridge Communications
media@intelliatx.com
mcrenson@tenbridgecommunications.com
Source: Intellia Therapeutics, Inc.
Continue Reading
